Navigation Links
Particle Sciences and Pernix Therapeutics Enter into an Agreement to Develop a Pediatric Dermatology Product
Date:3/21/2012

BETHLEHEM, Pa., March 21, 2012 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, today announced that it is developing with Pernix Therapeutics, a specialty pharmaceutical company, a new topical dermatology product for the pediatric market.

Mark Mitchnick, CEO of Particle Sciences, said, "There are multiple treatments for many pediatric skin conditions.  The unmet need is in the delivery of these agents via a more convenient, and improved vehicle.  Particle Sciences is applying advanced drug delivery and formulation technologies to an established pediatric product category.  For parents, this product is designed to be a potentially better and easier to use product."

Cooper Collins, Pernix Therapeutics' President and CEO, said, "We are enthusiastic about working with Particle Sciences for this product candidate, which may be another opportunity to further expand our pediatric product line."

Particle Sciences is an integrated provider of drug development services.  Particle Sciences focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and highly potent compounds across all dosage forms. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.comor contact us at (610) 861-4701 for information.

Contact:  Maureen Mattera, (610) 861-4701, mmattera@particlesciences.com


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics Drug Delivery Technology
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Particle Sciences Hires Robert Gwozdz to Head Oral Formulation
4. Brabender® Pharma USA, Inc. and Particle Sciences Cooperate to Expand Extrusion Capabilities
5. Particle Sciences Expands Its DOSE™ Program With Additional Proprietary Modeling Capabilities
6. Particle Sciences Granted Patent on Self Sterilizing Medical Devices
7. Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services
8. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
9. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
10. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
11. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May ... QGEN ; Frankfurt Prime Standard: QIA) today announced that ... with Therawis Diagnostics GmbH to develop and commercialize predictive assays ... market PITX2 as a marker to predict effectiveness of anthracycline ... "We are pleased to partner with Therawis, which ...
Breaking Medicine Technology:
(Date:5/28/2016)... ... May 28, 2016 , ... In a part of the city where’s it’s easy ... farm-to-table Kelowna restaurants is hoping to attract diners with a taste for real ... officially opened the doors to Cornerstone Grill, an urban casual restaurant focusing on dishes ...
(Date:5/27/2016)... Gilsum, New Hampshire (PRWEB) , ... May 27, 2016 , ... ... natural skin care products, announced today that it has been recognized as one of ... men entering parenthood. Badger was named as one of nine small businesses providing progressive ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... caregivers to casual readers, this installment is bolstered by inspiring human-interest stories, courtesy ... trends and tech within the industry, from leading advocates, associations and industry leaders ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... stories, which come courtesy of leaders in the nursing and health care industry. It ... advocates and associations—namely Abilene Christian University. , As the nursing industry is coming ...
(Date:5/26/2016)... DC (PRWEB) , ... May 26, 2016 , ... There ... National Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight ... dogs, 63 percent say grilling is their favorite way to cook a hot dog, ...
Breaking Medicine News(10 mins):